LBI-0609
THERAPEUTIC AREA
SOLID TUMOR CANCER
Indications
Neuroendocrine, Lung, Pancreas, TNBC (Breast) Cancer
REGULATORY PATHWAY
505(b)(2) with improved formulation
TARGET INDICATION
Immediate release taxane based nanomedicine with first of its kind drug resistant sensitizer
CURRENT DEVELOPMENT STATUS
Active pre-clinical development
NEXT DEVELOPMENT PHASE
IND enabling study
TIME TO HUMAN BENEFIT
Human trials beginning in 1.5 to 2 years
IMMEDIATE FUNDING REQUIRED?
Yes, please inquire